首頁 › 非小細胞肺癌 › 加州 › Huntington Beach
Huntington Beach, CA 的 非小細胞肺癌 臨床試驗
14 項針對 非小細胞肺癌 的研究正在 Huntington Beach(約 30 英里範圍內)及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本(英文)
正在為研究招募對象嗎?將此頁面置頂展示 — $99 / 30 天 →
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
招募中3 期
- City Of Hope - Seacliff /ID# 263143, Huntington Beach
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
招募中3 期
- Orange Coast Memorial Medical Center, Fountain Valley · 距離 4 英里
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Memorial Care Orange Coast Medical Center Attn, Fountain Valley · 距離 4 英里
- MemorialCare Orange Coast Medical Center, Fountain Valley · 距離 4 英里
- OC Blood and Cancer Care, Fountain Valley · 距離 4 英里
- 還有 1 項
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- City of Hope Seacliff, Huntington Beach
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
招募中3 期
- Research Site, Fountain Valley · 距離 4 英里
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
招募中2/3 期
- Local Institution - 007-777, Fountain Valley · 距離 4 英里
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
招募中3 期
- Orange Coast Memorial Medical Center Fountain Valley, Fountain Valley · 距離 4 英里
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
招募中1/2 期
- City of Hope, Huntington Beach
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
招募中2 期
- Compassionate Cancer Care Center, Fountain Valley · 距離 4 英里
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
招募中3 期
- MemorialCare - Orange Coast Medical Center, Fountain Valley · 距離 4 英里
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Research Site, Fountain Valley · 距離 4 英里
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
招募中2 期
- Los Angeles Cancer Network, Fountain Valley · 距離 4 英里
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
招募中2 期
- City of Hope Seacliff, Huntington Beach
GEMINI-NSCLC: NSCLC Biomarker Study
招募中觀察性研究
- MemorialCare, Fountain Valley · 距離 4 英里
其他城市的 非小細胞肺癌 試驗
- Houston, TX145 項研究
- New York City, NY121 項研究
- Arlington, VA104 項研究
- Nashville, TN97 項研究
- Boston, MA90 項研究
- Los Angeles, CA87 項研究
- St. Louis, MO73 項研究
- Chicago, IL61 項研究
- Baltimore, MD60 項研究
- San Antonio, TX59 項研究
- Columbus, OH57 項研究
- Washington, DC55 項研究
Huntington Beach 的其他研究
- 異位性皮膚炎(濕疹)8 項研究
- 肥胖症7 項研究
- 心房顫動7 項研究
- 乳癌6 項研究
- 癌症(所有類型)6 項研究
- 過重5 項研究
- 脂肪性肝病5 項研究
- 大腸直腸癌5 項研究
- 心臟衰竭5 項研究
- 第二型糖尿病4 項研究
- 牛皮癬關節炎4 項研究
- 結腸癌4 項研究
資料來源:ClinicalTrials.gov,擷取日期 2026年10月6日。各研究自行設定資格標準;由研究團隊決定參與者資格。